By examining their effects on cardiovascular mortality, heart failure hospitalizations, symptom relief, and renal outcomes, this study sought to assess the safety and therapeutic effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with heart failure across the whole spectrum of left ventricular ejection fraction. Here, SLC5A2 is linked to heart failure.